Milan, Italy- (WEBSITE ANNOUNCEMENT) – Deenova, announced today that following its unprecedented European market expansion and increasing new customer adoption, and to sustain its continuous new product developments, Deenova recently appointed Marco D’Incà as Pre-Sales, Solution Design and New Product Development Manager.
“I am thrilled to join Deenova, to further contribute to its International success.” said Marco D’Incà, “Deenova has demonstrated to be the raising star in the field of pharmacy automation with unique and unmatched solutions aimed at improving patient safety, quality of care and delivering strong financial benefits to healthcare institutions”.
After a long-established leadership on the Italian and French hospital pharmacy automation markets, Deenova has for the last 2 years benefited from a fast internationalization with successful market entries in countries such as United Kingdom, Germany, Spain, Malta and Poland with many other projects still to be announced. In addition the company recently announced the unveiling of three new innovative additions to its award winning D3 product line of mechatronic solutions, in conjunction with the 26th Congress of the European Association of Hospital Pharmacists, in Vienna.
Christophe Jaffuel, Deenova Chief Commercial Officer, stated: “We know Marco for many years as he is one of the pioneers in this industry. His strong technical expertise both in software and automation product development coupled with his international customer exposure are a great asset for Deenova in this period of unprecedented market expansion.”
Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere.
Deenova’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff.
Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.